Success Metrics

Clinical Success Rate
89.5%

Based on 17 completed trials

Completion Rate
89%(17/19)
Active Trials
2(9%)
Results Posted
65%(11 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_2
4
17%
Ph not_applicable
2
9%
Ph phase_1
3
13%
Ph phase_3
2
9%
Ph phase_4
5
22%

Phase Distribution

3

Early Stage

4

Mid Stage

7

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
3(18.8%)
Phase 2Efficacy & side effects
4(25.0%)
Phase 3Large-scale testing
2(12.5%)
Phase 4Post-market surveillance
5(31.3%)
N/ANon-phased studies
2(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.5%

17 of 19 finished

Non-Completion Rate

10.5%

2 ended early

Currently Active

2

trials recruiting

Total Trials

23

all time

Status Distribution
Active(2)
Completed(17)
Terminated(2)
Other(2)

Detailed Status

Completed17
unknown2
Recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
23
Active
2
Success Rate
89.5%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (18.8%)
Phase 24 (25.0%)
Phase 32 (12.5%)
Phase 45 (31.3%)
N/A2 (12.5%)

Trials by Status

unknown29%
completed1774%
recruiting29%
terminated29%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT04082962Phase 1

Dexamethasone Implant for Retinal Detachment in Uveal Melanoma

Completed
NCT04910503Phase 4

Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema

Recruiting
NCT06536491Phase 1

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

Recruiting
NCT05138029Phase 3

Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation

Unknown
NCT05600179

OCTA in Epivascular Glia After Dex Implant

Completed
NCT03953807Phase 4

A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated

Completed
NCT01571232Phase 2

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

Completed
NCT04619303Phase 4

Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO

Completed
NCT03889444

Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

Completed
NCT02951975

Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Terminated
NCT01427751Phase 4

Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion

Completed
NCT01805323

A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema

Completed
NCT01492400Phase 2

Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

Completed
NCT03003416

Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)

Completed
NCT02731911

Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

Completed
NCT02374060Phase 3

PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

Completed
NCT01945866Phase 2

Phase II Combination Steroid and Anti-VEGF for Persistent DME

Completed
NCT01673191Phase 2

A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

Completed
NCT01410201Not Applicable

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

Terminated
NCT01618266

Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23